Omeros (OMER) Trading Up 2.1%

Shares of Omeros Co. (NASDAQ:OMER) were up 2.1% on Thursday . The stock traded as high as $15.25 and last traded at $14.98. Approximately 940,616 shares changed hands during trading, a decline of 30% from the average daily volume of 1,344,563 shares. The stock had previously closed at $14.67.

Several analysts have recently weighed in on OMER shares. Bank of America raised their target price on Omeros from $2.44 to $4.00 in a research note on Wednesday, February 14th. ValuEngine downgraded Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Needham & Company LLC downgraded Omeros from a “buy” rating to a “hold” rating and set a $9.01 target price for the company. in a research note on Friday, March 2nd. Wedbush downgraded Omeros from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $47.00 to $19.00 in a research note on Friday, March 23rd. Finally, HC Wainwright set a $30.00 target price on Omeros and gave the company a “buy” rating in a research note on Tuesday, January 23rd. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. Omeros currently has an average rating of “Hold” and an average price target of $25.88.

The company has a market capitalization of $646.07, a P/E ratio of -19.15 and a beta of 3.62. The company has a quick ratio of 4.10, a current ratio of 4.12 and a debt-to-equity ratio of -29.93.



Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.03). The company had revenue of $13.76 million during the quarter, compared to analyst estimates of $21.94 million. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the business earned ($0.45) EPS. research analysts expect that Omeros Co. will post -1.51 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of OMER. Bank of New York Mellon Corp grew its stake in Omeros by 5.3% in the third quarter. Bank of New York Mellon Corp now owns 242,039 shares of the biopharmaceutical company’s stock worth $5,233,000 after purchasing an additional 12,080 shares in the last quarter. SG Americas Securities LLC grew its stake in Omeros by 138.9% in the third quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 7,067 shares in the last quarter. Wells Fargo & Company MN grew its stake in Omeros by 13.8% in the third quarter. Wells Fargo & Company MN now owns 42,144 shares of the biopharmaceutical company’s stock worth $911,000 after purchasing an additional 5,102 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Omeros by 10.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 217,804 shares of the biopharmaceutical company’s stock worth $4,709,000 after purchasing an additional 20,139 shares in the last quarter. Finally, Stifel Financial Corp grew its stake in Omeros by 10.7% in the third quarter. Stifel Financial Corp now owns 394,428 shares of the biopharmaceutical company’s stock worth $8,522,000 after purchasing an additional 38,268 shares in the last quarter. Institutional investors and hedge funds own 48.51% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Omeros (OMER) Trading Up 2.1%” was first posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://dakotafinancialnews.com/2018/04/12/omeros-omer-trading-up-2-1.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply